Patents by Inventor Alexei Bogdanov
Alexei Bogdanov has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9095625Abstract: There is provided a method of preparing nanoparticles and novel nanoparticles. The nanoparticle preparation comprises the generation of a mixture comprising a plurality of metal-containing compounds and a copolymer of a polyethylene glycol and an amine-containing polyamino acid such as polylysine where a metal core and polymer shell nanoparticle is formed. The novel nanoparticles have a metallic core and a graft copolymer shell of polyethylene glycol and an amine-containing polyamino acid where the shell least partially surrounds the metallic core and is non-ionically bound to the metallic core via metal-amine bonds.Type: GrantFiled: March 14, 2013Date of Patent: August 4, 2015Assignee: University of MassachusettsInventor: Alexei A. Bogdanov
-
Publication number: 20140065425Abstract: There is provided a method of preparing nanoparticles and novel nanoparticles. The nanoparticle preparation comprises the generation of a mixture comprising a plurality of metal-containing compounds and a copolymer of a polyethylene glycol and an amine-containing polyamino acid such as polylysine where a metal core and polymer shell nanoparticle is formed. The novel nanoparticles have a metallic core and a graft copolymer shell of polyethylene glycol and an amine-containing polyamino acid where the shell least partially surrounds the metallic core and is non-ionically bound to the metallic core via metal-amine bonds.Type: ApplicationFiled: March 14, 2013Publication date: March 6, 2014Applicant: UNIVERSITY OF MASSACHUSETTSInventor: Alexei A. Bogdanov
-
Patent number: 8563527Abstract: The present invention relates, in part, to an oligonucleotide-core carrier comprising a carrier, and oligonucleotide groups covalently linked to the carrier. The oligonucleotide groups are capable of dissociably linking load molecules such as therapeutic agents. The oligonucleotide-core carrier may also comprise protective side chains, and targeting molecules.Type: GrantFiled: August 19, 2008Date of Patent: October 22, 2013Assignee: Pharmain CorporationInventors: Gerardo M. Castillo, Elijah M. Bolotin, Alexei A. Bogdanov, Jr.
-
Patent number: 8486373Abstract: An intramolecularly-quenched, near infrared fluorescence probe that emits substantial fluorescence only after interaction with a target tissue (i.e., activation) is disclosed. The probe includes a polymeric backbone and a plurality of near infrared fluorochromes covalently linked to the backbone at fluorescence-quenching interaction-permissive positions separable by enzymatic cleavage at fluorescence activation sites. The probe optionally includes protective chains or fluorochrome spacers, or both. Also disclosed are methods of using the intramolecularly-quenched, near infrared fluorescence probes for in vivo optical imaging.Type: GrantFiled: November 1, 2004Date of Patent: July 16, 2013Assignee: The General Hospital CorporationInventors: Ralph Weissleder, Ching-Hsuan Tung, Umar Mahmood, Lee Josephson, Alexei Bogdanov
-
Patent number: 8153784Abstract: This invention relates to biochemistry and magnetic resonance imaging.Type: GrantFiled: July 7, 2005Date of Patent: April 10, 2012Assignee: The General Hospital CorporationInventors: Alexei Bogdanov, John W. Chen, Ralph Weissleder, Manel Querol
-
Patent number: 8084589Abstract: Described are phosphoramidite nucleoside analog monomers, precursors thereof, and oligonucleotides including one or more of the monomers. The monomers can be used during automated synthesis of oligonucleotide derivatives, and allow for incorporation of one or several reporter groups, organic molecules, bio-molecules, small molecules or other chemical groups at the internucleoside phosphotriesters. Oligonucleotides including the monomers have a number of uses in therapeutic, diagnostic, and research applications.Type: GrantFiled: August 29, 2008Date of Patent: December 27, 2011Assignees: University of Massachusetts, The General Hospital Corporation MassachusettsInventors: Alexei Bogdanov, Valeriy Metelev, David Tabatadze, Paul Zamecnik
-
Publication number: 20090136940Abstract: Described are phosphoramidite nucleoside analog monomers, precursors thereof, and oligonucleotides including one or more of the monomers. The monomers can be used during automated synthesis of oligonucleotide derivatives, and allow for incorporation of one or several reporter groups, organic molecules, bio-molecules, small molecules or other chemical groups at the internucleoside phosphotriesters. Oligonucleotides including the monomers have a number of uses in therapeutic, diagnostic, and research applications.Type: ApplicationFiled: August 29, 2008Publication date: May 28, 2009Applicants: University of Massachusetts, Massachusetts General HospitalInventors: Alexei Bogdanov, Valeriy Metelev, David Tabatadze, Paul Zamecnik
-
Publication number: 20090053169Abstract: The present invention relates, in part, to an oligonucleotide-core carrier comprising a carrier, and oligonucleotide groups covalently linked to the carrier. The oligonucleotide groups are capable of dissociably linking load molecules such as therapeutic agents. The oligonucleotide-core carrier may also comprise protective side chains, and targeting molecules.Type: ApplicationFiled: August 19, 2008Publication date: February 26, 2009Applicant: PharmaIN CorporationInventors: Gerardo M. Castillo, Elijah M. Bolotin, Alexei A. Bogdanov, JR., Sandra Reichstetter
-
Publication number: 20080044827Abstract: This invention relates to biochemistry and magnetic resonance imaging.Type: ApplicationFiled: July 7, 2005Publication date: February 21, 2008Inventors: Alexei Bogdanov, John Chen, Ralph Weissleder, Manel Querol
-
Patent number: 7153905Abstract: Hyperbranched dendron (HD) polymers are synthesized using low molecular weight polyethyleneimine (BPEI-L) as a core and used for gene delivery. The obtained polymers display low toxicity and efficient gene delivery at low nitrogen-to-phosphate (N/P) ratios. Using successive attachment of ethyleneimine moieties to a PEI core, the polymer has a lower relative ratio of linear-to-branched structures than in the core PEI. The more extensive branching enables the polymer to condense plasmid DNA into nanostructure complexes with a size of less than or equal to about 100 nm. The complexes are stable and efficient in transfecting cells in the presence of serum. Bioluminescent imaging of in vivo gene expression using a luciferase reporter gene performed in live mice showed gene expression in the liver and in submandibular lymph nodes.Type: GrantFiled: March 22, 2004Date of Patent: December 26, 2006Assignee: The General Hospital CorporationInventors: Pallab Banerjee, Wilfried Reichardt, Ralph Weissleder, Alexei Bogdanov
-
Publication number: 20060275775Abstract: An intramolecularly-quenched, near infrared fluorescence probe that emits substantial fluorescence only after interaction with a target tissue (i.e., activation) is disclosed. The probe includes a polymeric backbone and a plurality of near infrared fluorochromes covalently linked to the backbone at fluorescence-quenching interaction-permissive positions separable by enzymatic cleavage at fluorescence activation sites. The probe optionally includes protective chains or fluorochrome spacers, or both. Also disclosed are methods of using the intramolecularly-quenched, near infrared fluorescence probes for in vivo optical imaging.Type: ApplicationFiled: November 1, 2004Publication date: December 7, 2006Inventors: Ralph Weissleder, Ching-Hsuan Tung, Umar Mahmood, Lee Josephson, Alexei Bogdanov
-
Publication number: 20060258804Abstract: Hyperbranched dendron (HD) polymers are synthesized using low molecular weight polyethyleneimine (BPEI-L) as a core and used for gene delivery. The obtained polymers display low toxicity and efficient gene delivery at low nitrogen-to-phosphate (N/P) ratios. Using successive attachment of ethyleneimine moieties to a PEI core, the polymer has a lower relative ratio of linear-to-branched structures than in the core PEI. The more extensive branching enables the polymer to condense plasmid DNA into nanostructure complexes with a size of less than or equal to about 100 nm. The complexes are stable and efficient in transfecting cells in the presence of serum. Bioluminescent imaging of in vivo gene expression using a luciferase reporter gene performed in live mice showed gene expression in the liver and in submandibular lymph nodes.Type: ApplicationFiled: May 11, 2006Publication date: November 16, 2006Applicant: THE GENERAL HOSPITAL CORPORATION d/b/a MASSACHUSETTS GENERAL HOSPITALInventors: Pallab Banerjee, Wilfried Reichardt, Ralph Weissleder, Alexei Bogdanov
-
Publication number: 20050079149Abstract: Hyperbranched dendron (HD) polymers are synthesized using low molecular weight polyethyleneimine (BPEI-L) as a core and used for gene delivery. The obtained polymers display low toxicity and efficient gene delivery at low nitrogen-to-phosphate (N/P) ratios. Using successive attachment of ethyleneimine moieties to a PEI core, the polymer has a lower relative ratio of linear-to-branched structures than in the core PEI. The more extensive branching enables the polymer to condense plasmid DNA into nanostructure complexes with a size of less than or equal to about 100 nm. The complexes are stable and efficient in transfecting cells in the presence of serum. Bioluminescent imaging of in vivo gene expression using a luciferase reporter gene performed in live mice showed gene expression in the liver and in submandibular lymph nodes.Type: ApplicationFiled: March 22, 2004Publication date: April 14, 2005Inventors: Pallab Banerjee, Wilfried Reichardt, Ralph Weissleder, Alexei Bogdanov
-
Publication number: 20040241096Abstract: The invention features methods of detecting enzymatic activity (e.g., in a magnetic resonance image). In general, the methods include: (1) providing a monomeric substrate (e.g., a substrate that is polymerizable in the presence of an enzyme or as a result of an enzyme-catalyzed reaction), having the generic structure X-Y-Z, where X includes a chelator moiety having a chelated paramagnetic or superparamagnetic metal atom or ion, Y includes a linker moiety (e.g., to provide a covalent or non-covalent chemical bond or bonds between X and Z), and Z includes a polymerizing moiety; (2) contacting the substrate with a target tissue, wherein the substrate undergoes polymerization to form a paramagnetic or superparamagnetic polymer, the polymerization being catalyzed by an enzyme in an extracellular matrix or bound to the surfaces of cells of the target tissue; and (3) detecting an increase in relaxivity for the polymer relative to an equivalent amount of unpolymerized substrate.Type: ApplicationFiled: April 30, 2004Publication date: December 2, 2004Applicant: The General Hospital Corporation, a Massachusetts corporationInventors: Alexei Bogdanov, Ralph Weissleder
-
Patent number: 6737247Abstract: The invention features methods of detecting enzymatic activity (e.g., in a magnetic resonance image). In general, the methods include: (1) providing a monomeric substrate (e.g., a substrate that is polymerizable in the presence of an enzyme or as a result of an enzyme-catalyzed reaction), having the generic structure X-Y-Z, where X includes a chelator moiety having a chelated paramagnetic or superparamagnetic metal atom or ion, Y includes a linker moiety (e.g., to provide a covalent or non-covalent chemical bond or bonds between X and Z), and Z includes a polymerizing moiety; (2) contacting the substrate with a target tissue, wherein the substrate undergoes polymerization to form a paramagnetic or superparamagnetic polymer, the polymerization being catalyzed by an enzyme in an extracellular matrix or bound to the surfaces of cells of the target tissue; and (3) detecting an increase in relaxivity for the polymer relative to an equivalent amount of unpolymerized substrate.Type: GrantFiled: October 19, 2001Date of Patent: May 18, 2004Assignee: The General Hospital CorporationInventors: Alexei Bogdanov, Ralph Weissleder
-
Publication number: 20040022731Abstract: The invention relates to conjugates and methods for in vivo imaging of apoptosis using conjugates of fluorochromes and moieties that bind specifically to apoptotic cells. In specific embodiments, the fluorochrome emits fluorescence in the near-infrared range and is conjugated to a moiety, e.g., a protein such as annexin A5 or synaptotagmin, that binds specifically to apoptotic cells. The methods are non-invasive can be used to obtain images of apoptotic cells in the tissues of living animals, e.g., mammals such as humans.Type: ApplicationFiled: April 25, 2003Publication date: February 5, 2004Inventors: Alexei Bogdanov, Eyk Schellenberger, Alexander Petrovsky, Lee Josephson
-
Publication number: 20030219383Abstract: An intramolecularly-quenched, near infrared fluorescence probe that emits substantial fluorescence only after interaction with a target tissue (i.e., activation) is disclosed. The probe includes a polymeric backbone and a plurality of near infrared fluorochromes covalently linked to the backbone at fluorescence-quenching interaction-permissive positions separable by enzymatic cleavage at fluorescence activation sites. The probe optionally includes protective chains or fluorochrome spacers, or both. Also disclosed are methods of using the intramolecularly-quenched, near infrared fluorescence probes for in vivo optical imaging.Type: ApplicationFiled: February 7, 2003Publication date: November 27, 2003Applicant: The General Hospital Corporation, a Massachusetts corporationInventors: Ralph Weissleder, Ching-Hsuan Tung, Umar Mahmood, Lee Josephson, Alexei Bogdanov
-
Patent number: 6592847Abstract: An intramolecularly-quenched, near infrared fluorescence probe that emits substantial fluorescence only after interaction with a target tissue (i.e., activation) is disclosed. The probe includes a polymeric backbone and a plurality of near infrared fluorochromes covalently linked to the backbone at fluorescence-quenching interaction-permissive positions separable by enzymatic cleavage at fluorescence activation sites. The probe optionally includes protective chains or fluorochrome spacers, or both. Also disclosed are methods of using the intramolecularly-quenched, near infrared fluorescence probes for in vivo optical imaging.Type: GrantFiled: June 27, 2000Date of Patent: July 15, 2003Assignee: The General Hospital CorporationInventors: Ralph Weissleder, Ching-Hsuan Tung, Umar Mahmood, Lee Josephson, Alexei Bogdanov
-
Publication number: 20020142297Abstract: Described are short peptide sequences, termed recombinant peptide chelates (RPCs), and the imaging marker genes that encode them. The RPCs can be expressed in parallel with the expression of any other desired gene (e.g., a therapeutic gene), and used to easily confirm the expression of the therapeutic gene product. The RPCs are expressed in the cell or on the cell surface concurrently with the therapeutic gene product, and can be assayed by standard imaging techniques.Type: ApplicationFiled: December 18, 2000Publication date: October 3, 2002Applicant: The General Hospital Corporation, a Massachusetts corporationInventors: Alexei A. Bogdanov, Ralph Weissleder, Maria Simonova
-
Publication number: 20020127629Abstract: The invention features methods of detecting enzymatic activity (e.g., in a magnetic resonance image). In general, the methods include: (1) providing a monomeric substrate (e.g., a substrate that is polymerizable in the presence of an enzyme or as a result of an enzyme-catalyzed reaction), having the generic structure X-Y-Z, where X includes a chelator moiety having a chelated paramagnetic or superparamagnetic metal atom or ion, Y includes a linker moiety (e.g., to provide a covalent or non-covalent chemical bond or bonds between X and Z), and Z includes a polymerizing moiety; (2) contacting the substrate with a target tissue, wherein the substrate undergoes polymerization to form a paramagnetic or superparamagnetic polymer, the polymerization being catalyzed by an enzyme in an extracellular matrix or bound to the surfaces of cells of the target tissue; and (3) detecting an increase in relaxivity for the polymer relative to an equivalent amount of unpolymerized substrate.Type: ApplicationFiled: October 19, 2001Publication date: September 12, 2002Inventors: Alexei Bogdanov, Ralph Weissleder